Tessera Defense & Homeland Security Inc. (HLSQ) stock
Close on Nov 9, 2026Market cap $2.94MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.94M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$45.49M
- EPS, diluted
- $22.19
- Free cash flow
- -$26.39M
- Book value per share
- $1.05
- Diluted shares
- 10M
Trading
- Previous close
- $0.13
- Open
- $0.14
- Day's range
- $0.11 – $0.14
- Volume
- 3,945,026
- Average volume (20 days)
- 1,308,607
- Beta (5 years)
- 1.06
- 52-week range
- $0.11 – $85.00
- RSI (14 days)
- 21.0
- Volatility (1 year)
- 212.7%
- Relative volume
- 5.00×
- WACC
- 10.6%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 9, 2026. The S&P 500 is measured by the SPY fund.
| Period | HLSQ | S&P 500 | Difference | HLSQ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -61.4% | -3.3% | −58.1 pts | ||
| 3 months | -93.5% | -2.4% | −91.1 pts | ||
| Year to date | -99.4% | +11.2% | −110.7 pts | ||
| 1 year | -99.9% | +13.4% | −113.2 pts | ||
| 3 years | -99.9% | +79.9% | −179.8 pts | -88.6% | +21.6% |
| 5 years | -100.0% | +72.2% | −172.2 pts | -80.8% | +11.5% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tessera Defense & Homeland Security filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- Update
About Tessera Defense & Homeland Security
Services-Prepackaged Software
BiomX Inc. is a clinical-stage biotechnology company that develops therapies using natural and synthetic bacteriophage technologies. Its phage treatments are engineered to target and eliminate specific pathogenic bacteria associated with chronic medical conditions, particularly diabetic foot infections. The company's pipeline includes fixed multi-phage cocktails such as BX011 and personalized phage approaches like BX211, both designed to combat Staphylococcus aureus infections. These therapeutic candidates serve patient populations suffering from diabetic foot ulcers and diabetic foot osteomyelitis, offering alternatives or complements to conventional antibiotic regimens.
Company profile, executives and historyTessera Defense & Homeland Security stock: common questions
What is Tessera Defense & Homeland Security's stock price?
HLSQ closed at $0.11 on Nov 9, 2026, down 15.38% on the day. Over the past 52 weeks it traded between $0.11 and $85.00.
What is Tessera Defense & Homeland Security's market cap?
Tessera Defense & Homeland Security was worth $2.94M at the close on Nov 9, 2026: the share price times the diluted shares outstanding.
Does Tessera Defense & Homeland Security pay a dividend?
No. Tessera Defense & Homeland Security has not paid a cash dividend over the last twelve months.
How has HLSQ stock performed over the past year?
Including dividends, HLSQ returned -99.9% over the past year, against +13.4% for the S&P 500.
How many HLSQ shares are sold short?
0M shares were sold short at the latest FINRA report, 1.93% of the float, or 1.0 days of average trading volume.
Who are Tessera Defense & Homeland Security's competitors?
Companies most similar to Tessera Defense & Homeland Security by business, industry and size include DFSC, KOAN, CLOQ, IDAI, VWAV.
See a number that looks wrong?